Hematological Safety Profile of Lu-PSMA-617 therapy: Identifying Patients at Risk for Cytopenia (EANM 2026) - Sep 29, 2026 - Abstract #EP-0918; "¹⁷⁷Lu-PSMA RLT is associated with predominantly mild-to-moderate hematological toxicity, with low incidence of severe cytopenia. Baseline leukocyte count is a key predictor of toxicity and may be used for risk stratification. The findings support the safety and tolerability of RLT with appropriate patient selection and monitoring."
Clinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor
|
|
A. Nazar; M. Ora; P. Pradhan; A. Gupta
|